No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 3.0x · 10Y median 18.1x · 2nd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T20:08:15.087Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for PROCEPT BioRobotics Corporation (PRCT) stock was $17.51 as of Oct 6, 2026, 4:00 PM EDT, down 1.74% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -50.3% · 3-year avg -15.8%/yr · 5-year avg -14.4%/yr
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures.
Medical - Devices · San Jose, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
-0.39
Revenue Est.
$100.84M
Last Quarter Results
EPS
$-0.47
vs Estimate
$-0.45
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PRCT | $996.65M | $17.51 | -1.74% | -50.29% | -14.36% | N/A | N/A |
| 2CGEM | $998.69M | $16.25 | +1.31% | +170.57% | -7.48% | N/A | vs PRCT |
| 3VOR | $992.14M | $18.31 | -1.45% | -50.23% | -42.54% | N/A | vs PRCT |
| 4IMTX | $1.01B | $7.50 | -2.98% | -17.69% | -9.88% | N/A | vs PRCT |
| 5LBRX | $982.46M | $34.26 | -1.04% | +129.12% | N/A | N/A | vs PRCT |
| 6MGTX | $981.66M | $10.60 | -2.93% | +29.07% | -3.10% | N/A | vs PRCT |
forward FY estimate
N/A
$94.50M
vs Estimate
$92.77M
Consensus Rating
Based on 11 analysts
Average Price Target
$21.73
+24.1% upside
Low
$16.00
Current
$17.51
High
$28.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.42 | $-0.39 | $-0.35 | 7 |
| Quarter ending Dec 2026 | $-0.29 | $-0.25 | $-0.23 | 7 |
| Quarter ending Mar 2027 | $-0.40 | $-0.39 | $-0.38 | 2 |
| Quarter ending Jun 2027 | $-0.34 | $-0.33 | $-0.32 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.69 | $-1.67 | $-1.62 | 9 |
| FY 2027 | $-1.40 | $-1.13 | $-0.87 | 9 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $98.65M | $100.84M | $103.61M | 8 |
| Quarter ending Dec 2026 | $116.85M | $117.59M | $118.04M | 8 |
| Quarter ending Mar 2027 | $102.64M | $104.81M | $107.15M | 4 |
| Quarter ending Jun 2027 | $112.06M | $114.44M | $116.99M | 5 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $393.52M | $395.41M | $398.58M | 10 |
| FY 2027 | $462.74M | $476.76M | $489.28M | 10 |
